Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 725.28

+3.0%

Nov 18 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (203)	1/29/1998 3:03:00 AM
From: Miljenko Zuanic	Read Replies (1) of 3559

Rick and others: I think that REGN learned lesson with BDGF. One may have learned great deal of specific protein function, still putting protein in body to work for specific indication does not guaranty success. REGN know that they will not have many new chances, so better they be very sure what are they doing with next one. Main problem for early stage bt is rush from discovery to preclinical/clinical study. Greatly pushed with hungry VC and greedy founders. No surprise that many failed and will continue with failure. REGN is building solid foundation. Investing in science will always bring return if is not limited with time frame and pure jugment, imo. Normally, REGN is not science institution, it is public company which is driven by investment and profit. But profit can kill science (AMGN), and science (nonproductive) can kill investment (REGN today appears like this one :( ). But is this real story? Link to REGN business plan(Jan. 97): busesswire.com I agree that investors are confused and should demand clear description and status of all their projects? Business plan and how they intend to realize it and put at work? Time frame for progress in preclinical and clinical study? Status of collaboration: AMGN, PCOP, MRK, P&G, Sumitomo? Your wish list for Schleifer cover very well my own. I only can add that they regularly inform investors about company progress and development. Not only readers of scientific journals and scientific conference attenders. They are not science institution, they are public company. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next